Novo Nordisk Plans Value-based Contracts For GLP-1 Agonist Ozempic
Executive Summary
Company aims to shift gradually away from once-daily GLP-1 Victoza (liraglutide) toward once-weekly Ozempic (semaglutide).
You may also be interested in...
Novo Anticipates Q4 Soft Launch For Closely Watched Oral GLP-1 Agent Rybelsus In The US
US CMO Todd Hobbs told Scrip the full launch will be in early 2020 as sales, manufacturing and reimbursement preparations for oral semaglutide continue based on the now-approved FDA label in type 2 diabetes.
In Conversation With Novo Nordisk CMO: The Ongoing Fight Against Diabetes
Stephen Gough has kept his connections with Oxford University and will see collaborations between the two expand next month with the opening of the Novo Nordisk Research Centre Oxford. The executive spoke to Scrip.
Novo Nordisk Touts First-Line Potential For Oral Semaglutide
Novo's oral GLP-1 receptor agonist has a lot going for it in diabetes based on the latest data, but still needs to prove cardiovascular benefit; a new large outcomes study is now in the works.